Farhad Zaker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Farhad Zaker has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Akbar Dorgalaleh
Ali Asghar Clinical Research Development Centre (AACRDC), Department of Pediatrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2 shared publications Abbas Ahmadi
Cellular & Molecular Research Center Kurdistan University of Medical Sciences Sanandaj Iran
1 shared publicationBehnaz Tavasoli
Department of Hematology and Blood Banking Faculty of Allied Medicine Iran University of Medical Sciences Tehran Iran
1 shared publication- Ebrahim Kalantar
Smart University of Medical Sciences Tehran Iran
1 shared publication Farahnaz Rezaei Makhouri
Department of Chemistry Faculty of Sciences University of Tehran Tehran Iran
1 shared publication- Jahan Bakhsh Ghasemi
Chemistry Faculty, School of Sciences, University of Tehran, Tehran, Iran
1 shared publication
Latest Publications
- 27 May 2025
- Published by Wiley in Haemophilia
- Vol. 31 (4) , 771-779
Factor VII Padua in Iran: A Study on 150 Patients With Factor VII Deficiency
Introduction: Factor (F) VII Padua is an ultra‐rare type II FVII deficiency characterized by discrepancies in FVII activity across different thromboplastin types. Due to the high prevalence of consanguineous marriages in Iran, rare bleeding disorders, including FVII deficiency, are more common. Accurate identification of FVII Padua is critical to avoid inappropriate treatments and thrombotic risks. Aim: This study aimed to determine the incidence and clinical and laboratory characteristics of FVII Padua among Iranian patients with FVII deficiency. Method: One hundred fifty Iranian patients aged 18 years or older with confirmed FVII deficiency were included. PT testing was performed using rabbit brain, human placenta and recombinant human thromboplastins. Patients with PT discrepancies consistent with FVII Padua underwent genetic analysis of F7 exon 9 for the Arg364Gln mutation. Results: Thirteen patients (8.6%) exhibited PT patterns indicative of FVII Padua. HRM analysis identified nine heterozygous and two homozygous cases for the Padua variant; subsequently, sequencing analysis confirmed the Arg364Gln variant in two patients. Sequencing also revealed four additional variants in exon 9. The confirmed Padua cases presented diverse manifestations, ranging from asymptomatic to symptomatic, including bruising, epistaxis, gastrointestinal bleeding and gum bleeding. Conclusion: FVII Padua is relatively prevalent among Iranian patients with FVII deficiency . Molecular testing is essential for accurate diagnosis, enabling appropriate management and preventing unnecessary interventions. Tailored diagnostic strategies are crucial in regions with high consanguinity rates to optimize patient care and reduce thrombotic risks.
- 27 May 2025
- Published by Wiley in Haemophilia
- Vol. 31 (4) , 771-779
Factor VII Padua in Iran: A Study on 150 Patients With Factor VII Deficiency
Introduction: Factor (F) VII Padua is an ultra‐rare type II FVII deficiency characterized by discrepancies in FVII activity across different thromboplastin types. Due to the high prevalence of consanguineous marriages in Iran, rare bleeding disorders, including FVII deficiency, are more common. Accurate identification of FVII Padua is critical to avoid inappropriate treatments and thrombotic risks. Aim: This study aimed to determine the incidence and clinical and laboratory characteristics of FVII Padua among Iranian patients with FVII deficiency. Method: One hundred fifty Iranian patients aged 18 years or older with confirmed FVII deficiency were included. PT testing was performed using rabbit brain, human placenta and recombinant human thromboplastins. Patients with PT discrepancies consistent with FVII Padua underwent genetic analysis of F7 exon 9 for the Arg364Gln mutation. Results: Thirteen patients (8.6%) exhibited PT patterns indicative of FVII Padua. HRM analysis identified nine heterozygous and two homozygous cases for the Padua variant; subsequently, sequencing analysis confirmed the Arg364Gln variant in two patients. Sequencing also revealed four additional variants in exon 9. The confirmed Padua cases presented diverse manifestations, ranging from asymptomatic to symptomatic, including bruising, epistaxis, gastrointestinal bleeding and gum bleeding. Conclusion: FVII Padua is relatively prevalent among Iranian patients with FVII deficiency . Molecular testing is essential for accurate diagnosis, enabling appropriate management and preventing unnecessary interventions. Tailored diagnostic strategies are crucial in regions with high consanguinity rates to optimize patient care and reduce thrombotic risks.
- 8 July 2020
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (5) , 619-627
Molecular and clinical profile of congenital fibrinogen disorders in Iran, identification of two novel mutations
Introduction Congenital fibrinogen disorders (CFDs) comprise the quantitative and qualitative fibrinogen molecule abnormalities that are caused by fibrinogen gene mutations. The objective of this cohort research was to study the molecular and clinical profiles of patients with CFDs. Materials and methods Genomic DNA Sanger sequencing of 14 Iranian patients was performed to determine CFDs‐causing mutations. The disorders were diagnosed by routine and specific (fibrinogen antigen and functional assay) coagulation tests, and clinical data were obtained from medical records. Molecular dynamics (MD) simulations were performed to investigate the effect of missense mutation on the protein structure. Results Thirteen out of 14 patients had afibrinogenemia while the remaining patient had dysfibrinogenemia. Umbilical cord bleeding was the most common clinical presentation (n: 9, ~70%) which led to the diagnosis of afibrinogenemia, while menorrhagia led to the diagnosis of dysfibrinogenemia. Six homozygous mutations were identified in afibrinogenemia: three previously described variants in FGA (p.Trp52Ter, p.Ser312AlafsTer109 and p.Gly316GlufsTer105), one in FBG (p.Gly430Asp), and two novel mutations in FGB (p.Gly430Arg) and FGG (p.His366ThrfsTer40), while the FGA (p.Arg38Thr) heterozygous mutation was identified in dysfibrinogenemia. MD simulation indicated that the FGA p. Arg38Thr mutation probably interferes with polymerization of fibrin monomers. Conclusions In Iran, with its high rate of consanguinity, autosomal recessive afibrinogenemia with severe clinical presentations is relatively common due to heterogeneous molecular defects.
- 8 July 2020
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (5) , 619-627
Molecular and clinical profile of congenital fibrinogen disorders in Iran, identification of two novel mutations
Introduction Congenital fibrinogen disorders (CFDs) comprise the quantitative and qualitative fibrinogen molecule abnormalities that are caused by fibrinogen gene mutations. The objective of this cohort research was to study the molecular and clinical profiles of patients with CFDs. Materials and methods Genomic DNA Sanger sequencing of 14 Iranian patients was performed to determine CFDs‐causing mutations. The disorders were diagnosed by routine and specific (fibrinogen antigen and functional assay) coagulation tests, and clinical data were obtained from medical records. Molecular dynamics (MD) simulations were performed to investigate the effect of missense mutation on the protein structure. Results Thirteen out of 14 patients had afibrinogenemia while the remaining patient had dysfibrinogenemia. Umbilical cord bleeding was the most common clinical presentation (n: 9, ~70%) which led to the diagnosis of afibrinogenemia, while menorrhagia led to the diagnosis of dysfibrinogenemia. Six homozygous mutations were identified in afibrinogenemia: three previously described variants in FGA (p.Trp52Ter, p.Ser312AlafsTer109 and p.Gly316GlufsTer105), one in FBG (p.Gly430Asp), and two novel mutations in FGB (p.Gly430Arg) and FGG (p.His366ThrfsTer40), while the FGA (p.Arg38Thr) heterozygous mutation was identified in dysfibrinogenemia. MD simulation indicated that the FGA p. Arg38Thr mutation probably interferes with polymerization of fibrin monomers. Conclusions In Iran, with its high rate of consanguinity, autosomal recessive afibrinogenemia with severe clinical presentations is relatively common due to heterogeneous molecular defects.